
浏览全部资源
扫码关注微信
纸质出版:2015
移动端阅览
王健,徐杰,安雪青,吕健东.雌激素活化GPER介导的IL-6/STAT3通路促进乳腺癌细胞SKBR-3增殖作用[J].陆军军医大学学报(原第三军医大学学报),2015,37(04):340-345.
Wang Jian,Xu Jie,An Xueqing,Lyu Jiandong.Estrogen activates GPER mediated IL-6/STAT3 signaling pathway to enhance proliferation in breast cancer SKBR-3 cells[J].J Amry Med Univ (J Third Mil Med Univ),2015,37(04):340-345.
王健,徐杰,安雪青,吕健东.雌激素活化GPER介导的IL-6/STAT3通路促进乳腺癌细胞SKBR-3增殖作用[J].陆军军医大学学报(原第三军医大学学报),2015,37(04):340-345. DOI:
Wang Jian,Xu Jie,An Xueqing,Lyu Jiandong.Estrogen activates GPER mediated IL-6/STAT3 signaling pathway to enhance proliferation in breast cancer SKBR-3 cells[J].J Amry Med Univ (J Third Mil Med Univ),2015,37(04):340-345. DOI:
目的 探讨雌激素活化膜性雌激素受体(G-protein coupled estrogen receptor
GPER)所介导的IL-6/STAT3炎症信号通路对乳腺癌SKBR-3细胞增殖能力的影响。 方法 用17-β雌二醇(E
2
)、GPER特异性激动剂(G1)、GPER特异性拮抗剂(G15)、IL-6中和抗体(Anti-IL-6)及STAT3特异性抑制剂JSI-124(cucurbitacin I)药物处理SKBR-3细胞后,分别得到对照组、E
2
处理组、G1处理组、E
2
+G15处理组、G1+G15处理组、E
2
+Anti-IL-6处理组、G1+Anti-IL-6处理组、E
2
+JSI-124处理组与G1+JSI-124处理组,用ELISA检测细胞培养液上清中IL-6的分泌量,CCK-8法检测细胞增殖能力的变化,Western blot检测细胞中p-STAT3与STAT3的蛋白表达水平。 结果 E
2
和G1显著促进SKBR-3细胞上清中IL-6 的分泌量,G15可显著阻断其分泌(P0.05)。E
2
及G1药物处理细胞后增殖能力较对照组显著增强,相对细胞数分别为对照组的(1.68±0.13)倍与(1.74±0.21)倍,其促增殖作用被G15及IL-6中和抗体(Anti-IL-6)显著抑制(P0.05)。E
2
及G1在不同时间点(1、3、6、12 h)均可显著促进细胞中p-STAT3 的蛋白表达量,分别于12 h和3 h达到表达峰值,其蛋白相对表达量分别为对照组的(2.54±0.23)倍和(3.12±0.24)倍。G15、Anti-IL-6及JSI-124显著阻断以上变化(P0.05)。JSI-124亦可明显抑制E
2
及G1所引起的促增殖效应(P0.05)。 结论 雌激素活化膜性雌激素受体GPER促进乳腺癌SKBR-3细胞自分泌IL-6从而激活细胞中下游STAT3炎症信号通路,同时,GPER/IL-6/STAT3信号通路也介导了雌激素对细胞的增殖作用。
Objective To determine the effects of estrogen activation in the G-protein coupled estr
ogen receptor (GPER) mediated-6/STAT3 (GPER/IL-6/STAT3) signaling pathway on the cell proliferation in breast cancer SKBR-3 cells. Methods 17-β-estradiol (E
2
)
GPER specific agonist (G1)
GPER specific antagonist (G15)
human IL-6-neutralizing antibody (anti-IL-6) and STAT3 signaling specific inhibitor (cucurbitacin I
JSI-124) were used respectively to treat SKBR-3 cells. So the cells were accordingly assigned into the control group
E
2
treatment group
G1 treatment group
E
2
+G15 treatment group
G1+G15 treatment group
E
2
+anti-IL-6 treatment group
G1+anti-IL-6 treatment group
E
2
+JSI-124 treatment group and G1+JSI-124 treatment group. The content of IL-6 in the supernatant was detected by ELISA. CCK-8 assay was used to test the change of proliferate ability
and Western blotting to the protein expression levels of p-STAT3 and STAT3. Results E
2
and G1 significantly increased the content of IL-6 in the supernatant which could be blocked by GPER specific antagonist (G15) (P0.05). After treating with E
2
and G1 in the SKBR-3 cells
the cell proliferation was increased remarkably compared with control groups
with the relative cell amount of 1.68±0.13 and 1.74±0.21 times higher than those of the control groups (P0.05). However
the growth effects could be significantly blocked by G15 and anti-IL-6 (P0.05). E
2
and G1 enhanced the protein expression of p-STAT3 in 1
3
6
and 12 h after treatment
and the protein level reached the peak values at 12 h and 3 h respectively in E
2
treatment group and G1 treatment group
with the relative protein expressions of 2.54±0.23 and 3.12±0.24 times higher than those of the control groups. G15
anti-IL-6 and JSI-124 blocked the above changes (P0.05). Furthermore
JSI-124 also inhibited the growth effects induced by E
2
and G1 as well as G15 and anti-IL-6 (P0.05). Conclusion Estrogen activates the membrane estrogen receptor GPER to en
hance the autocrine secretion of IL-6 which activates its downstream STAT3 inflammatory signal pathway. Moreover
the GPER/IL-6/STAT3 signal pathway mediates the cell proliferation induced by estrogen.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621